PMID: 8938522Oct 1, 1996Paper

Increased frequency of TCR gamma delta + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia

Journal of Hematotherapy
Lawrence S LambA P Gee

Abstract

Recent interest has focused on the function of gamma delta + T cells in immune responses. However, their role in allogeneic bone marrow transplantation (BMT) remains undefined. We report on a group of 43 leukemia patients who survived for at least 100 days following transplantation using partially HLA-mismatched grafts from related donors that were T cell depleted with the anti-TCR alpha beta monoclonal antibody T10B9.1A-31 and complement. Ten patients (23.2%) were found to have an increased (> or = 10%) proportion of gamma delta + T cells in the peripheral blood at 60-270 days after BMT. All of these patients remain alive, and 9 (90% of patients with > or = 10% gamma delta + cells) are free of disease at 2.5 years compared with a disease-free survival probability of 31% among patients with a normal proportion and concentration of gamma delta + T cells. No other factor was found to be independently associated with improved survival in these patients. These data suggest a possible association between an increase in the percentage and number of gamma delta + T cells and improved disease-free survival following transplantation from a partially mismatched related donor.

Citations

Dec 6, 2005·Cancer Immunology, Immunotherapy : CII·Paul F MeehLawrence S Lamb
May 3, 2011·Surgery Today·Yukihiro YoshidaKazuhiro Kakimi
Sep 28, 2002·Blood Reviews·Mahmoud AljurfMohamed O Musa
Jan 9, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Drew C DenigerLaurence J N Cooper
Jul 27, 2001·British Journal of Haematology·M W LowdellH G Prentice
Oct 6, 2005·Proceedings of the National Academy of Sciences of the United States of America·Jena D FrenchRebecca L O'brien
Jul 10, 2004·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·K A Al-Anazi, S Jacobs
May 31, 2013·British Journal of Haematology·Claire BoothPaul Veys
Jan 8, 2015·Frontiers in Immunology·Drew C DenigerLaurence J N Cooper
Dec 1, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·John S ThompsonGordon Phillips
Aug 16, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Giuseppina Li PiraFranco Locatelli
Nov 26, 2011·Pathology, Research and Practice·Nicola DanieleFrancesco Zinno
Oct 28, 2008·Burns : Journal of the International Society for Burn Injuries·Martin G Schwacha
Nov 29, 2016·Cellular & Molecular Immunology·Dang WuJian Huang
Feb 23, 2018·International Journal of Molecular Sciences·Alice Bertaina, Marco Andreani
Jan 24, 2018·Blood·Rupert Handgretinger, Karin Schilbach
Jul 14, 2000·Journal of Hematotherapy & Stem Cell Research·J Barrett, R Childs
Apr 9, 2019·American Journal of Respiratory Cell and Molecular Biology·Edmund K Moon
Sep 8, 2019·Nature Reviews. Drug Discovery·Zsolt SebestyenJurgen Kuball
Jul 12, 2018·Transplantation·Oliver McCallionFadi Issa
Feb 10, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jena D FrenchRebecca L O'Brien
Mar 11, 2015·Scandinavian Journal of Immunology·L Minculescu, H Sengeløv
Jul 5, 2017·Biomedicines·Haitham AbdelhakimAyman Saad
May 1, 2018·Stem Cells International·Sofia BerglundMichael Uhlin
Jun 6, 2018·Frontiers in Immunology·Vito PistoiaLorenzo Moretta
Mar 3, 2020·Frontiers in Immunology·Susanne H C BaumeisterRizwan Romee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.